MNKD
MannKind Corporation
Price Chart
Latest Quote
$3.88
-0.05 (-1.15%)
Current Price
| Previous Close | $3.93 |
| Open | $3.94 |
| Day High | $3.99 |
| Day Low | $3.88 |
| Volume | 1,797,456 |
Stock Information
| Shares Outstanding | 308.95M |
| Total Debt | $434.15M |
| Cash Equivalents | $133.86M |
| Revenue | $360.78M |
| Net Income | $-23.91M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.20B |
| EPS (TTM) | $-0.07 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.51B |
| Sales | $360.78M |
| Income | $-23.91M |
| Book/sh | $-0.19 |
| Cash/sh | $0.43 |
| Employees | 591 |
Financial Ratios
| Quick Ratio | 1.43 |
| Current Ratio | 1.87 |
Returns & Margins
| ROA | 2.03% |
| Gross Margin | 75.63% |
| Operating Margin | -3.31% |
| Profit Margin | -6.63% |
Ownership
| Insider Ownership | 1.55% |
| Institutional Ownership | 59.29% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 20.18 |
| PEG | 4.39 |
| P/S | 3.33 |
| P/B | -20.23 |
Analyst Data
| Recommendation | none |
| Target Price | $7.59 |
Technical Indicators
| SMA20 | $3.68 |
| SMA50 | $3.28 |
| SMA200 | $4.51 |
| RSI | 68.55 |
| ATR | 0.1907 |
| Shares Float | 303.07M |
| Short Float | 9.95% |
| Short Ratio | 4.17 |
| Volatility | 1.11 |
| Rel Volume | 0.32 |
Performance History
| Week | +0.39% |
| Month | +14.94% |
| Quarter | +69.65% |
| 6 Months | -33.48% |
| YTD | -30.62% |
| Year | +2.24% |
| 3 Years | -5.01% |
| 5 Years | -10.28% |
| 10 Years | -37.84% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $3.88 | 1,798,037 |
| 2026-06-23 | $3.93 | 2,985,900 |
| 2026-06-22 | $3.89 | 3,563,000 |
| 2026-06-18 | $3.94 | 16,623,000 |
| 2026-06-17 | $3.92 | 3,665,300 |
| 2026-06-16 | $3.87 | 3,163,900 |
| 2026-06-15 | $4.00 | 5,605,200 |
| 2026-06-12 | $3.66 | 3,844,000 |
| 2026-06-11 | $3.75 | 4,071,300 |
| 2026-06-10 | $3.63 | 4,478,300 |
| 2026-06-09 | $3.57 | 4,907,700 |
| 2026-06-08 | $3.39 | 2,349,400 |
| 2026-06-05 | $3.40 | 3,245,400 |
| 2026-06-04 | $3.52 | 3,519,400 |
| 2026-06-03 | $3.36 | 3,494,700 |
| 2026-06-02 | $3.43 | 7,025,000 |
| 2026-06-01 | $3.53 | 8,345,300 |
| 2026-05-29 | $3.77 | 20,391,900 |
| 2026-05-28 | $3.64 | 5,464,400 |
| 2026-05-27 | $3.55 | 3,581,400 |
| 2026-05-26 | $3.53 | 3,697,300 |
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
đ° Latest News
Wells Fargo Calls MannKind Corporation (MNKD)âs Commercial Potential a âShow-Me Storyâ
Insider Monkey âĸ 2026-06-13T15:31:05Z
MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data
Simply Wall St. âĸ 2026-06-12T02:13:38Z
Jim Cramer Says He Blessed MannKind as a Speculation Only
Insider Monkey âĸ 2026-06-08T15:34:26Z
MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy
Insider Monkey âĸ 2026-06-05T21:56:46Z
MannKind (MNKD) Is Up 11.5% After Afrezza Pediatric Approval And Trial Relief - Has The Bull Case Changed?
Simply Wall St. âĸ 2026-06-01T08:12:13Z
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market
MarketBeat âĸ 2026-05-31T03:07:46Z
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children
Stocktwits âĸ 2026-05-29T19:43:45Z
MNKD Stock Eyes Best Month Since 2022 Ahead Of FDA Decision On Pediatric Diabetes Treatment
Stocktwits âĸ 2026-05-28T11:19:53Z
MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2M
Insider Monkey âĸ 2026-05-18T04:50:12Z
ARKO Petroleum And 2 Other Value Stocks Priced Below Estimated Worth
Simply Wall St. âĸ 2026-05-13T17:38:27Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $79,649,000 | $69,231,000 | $58,236,000 | $57,497,000 |
| Cost Of Revenue | $87,960,000 | $76,602,000 | $62,771,000 | $57,497,000 |
| Total Revenue | $348,966,000 | $285,504,000 | $198,962,000 | $99,770,000 |
| Operating Revenue | $402,919,000 | $339,302,000 | $255,394,000 | $99,770,000 |
| Expenses | ||||
| Interest Expense | $37,822,000 | $37,772,000 | $24,953,000 | $24,769,000 |
| Total Expenses | $302,416,000 | $216,824,000 | $188,368,000 | $168,691,000 |
| Other Income Expense | $-15,167,000 | $-12,796,000 | $-1,964,000 | $3,777,000 |
| Other Non Operating Income Expenses | $-1,009,000 | $32,000 | $122,000 | $-102,000 |
| Net Non Operating Interest Income Expense | $-29,976,000 | $-25,366,000 | $-19,007,000 | $-22,256,000 |
| Total Other Finance Cost | $207,000 | $209,000 | $208,000 | - |
| Interest Expense Non Operating | $37,822,000 | $37,772,000 | $24,953,000 | $24,769,000 |
| Operating Expense | $214,456,000 | $140,222,000 | $125,597,000 | $111,194,000 |
| Selling And Marketing Expense | - | - | $51,776,000 | $53,753,000 |
| General And Administrative Expense | - | - | $42,538,000 | $37,720,000 |
| Other Operating Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $5,863,000 | $27,588,000 | $-11,938,000 | $-87,400,000 |
| Net Interest Income | $-29,976,000 | $-25,366,000 | $-19,007,000 | $-22,256,000 |
| Interest Income | $8,053,000 | $12,615,000 | $6,154,000 | $2,513,000 |
| Normalized Income | $17,047,820 | $39,184,512 | $-10,290,060 | $-91,279,000 |
| Net Income From Continuing And Discontinued Operation | $5,863,000 | $27,588,000 | $-11,938,000 | $-87,400,000 |
| Total Operating Income As Reported | $38,801,000 | $72,587,000 | $8,678,000 | $-64,110,000 |
| Net Income Common Stockholders | $5,863,000 | $27,588,000 | $-11,938,000 | $-87,400,000 |
| Net Income | $5,863,000 | $27,588,000 | $-11,938,000 | $-87,400,000 |
| Net Income Including Noncontrolling Interests | $5,863,000 | $27,588,000 | $-11,938,000 | $-87,400,000 |
| Net Income Continuous Operations | $5,863,000 | $27,588,000 | $-11,938,000 | $-87,400,000 |
| Pretax Income | $1,407,000 | $30,518,000 | $-10,377,000 | $-87,400,000 |
| Special Income Charges | $-6,409,000 | $-16,735,000 | $-170,000 | $0 |
| Interest Income Non Operating | $8,053,000 | $12,615,000 | $6,154,000 | $2,513,000 |
| Operating Income | $46,550,000 | $68,680,000 | $10,594,000 | $-68,921,000 |
| Depreciation Amortization Depletion Income Statement | $3,973,000 | $0 | $0 | - |
| Depreciation And Amortization In Income Statement | $3,973,000 | $0 | $0 | - |
| Amortization Of Intangibles Income Statement | $3,973,000 | $0 | $0 | - |
| Gross Profit | $261,006,000 | $208,902,000 | $136,191,000 | $42,273,000 |
| Per Share | ||||
| Diluted EPS | $0.02 | $0.10 | $-0.04 | $-0.34 |
| Basic EPS | $0.02 | $0.10 | $-0.04 | $-0.34 |
| Other | ||||
| Tax Effect Of Unusual Items | $-2,973,180 | $-1,231,488 | $-438,060 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $65,671,000 | $88,489,000 | $21,197,000 | $-60,198,000 |
| Total Unusual Items | $-14,158,000 | $-12,828,000 | $-2,086,000 | $3,879,000 |
| Total Unusual Items Excluding Goodwill | $-14,158,000 | $-12,828,000 | $-2,086,000 | $3,879,000 |
| Reconciled Depreciation | $12,284,000 | $7,371,000 | $4,535,000 | $6,312,000 |
| EBITDA (Bullshit earnings) | $51,513,000 | $75,661,000 | $19,111,000 | $-56,319,000 |
| EBIT | $39,229,000 | $68,290,000 | $14,576,000 | $-62,631,000 |
| Diluted Average Shares | $314,112,000 | $283,844,000 | $267,014,000 | $257,092,000 |
| Basic Average Shares | $305,639,000 | $274,415,000 | $267,014,000 | $257,092,000 |
| Diluted NI Availto Com Stockholders | $5,863,000 | $27,588,000 | $-11,938,000 | $-87,400,000 |
| Tax Provision | $-4,456,000 | $2,930,000 | $1,561,000 | $0 |
| Write Off | $6,409,000 | $1,550,000 | $170,000 | $0 |
| Restructuring And Mergern Acquisition | $0 | $-5,259,000 | $0 | $0 |
| Gain On Sale Of Security | $-7,749,000 | $3,907,000 | $-1,916,000 | $3,879,000 |
| Amortization | $3,973,000 | $0 | $0 | - |
| Research And Development | $66,348,000 | $45,893,000 | $31,283,000 | $19,721,000 |
| Selling General And Administration | $144,135,000 | $94,329,000 | $94,314,000 | $91,473,000 |
| Other Special Charges | - | $20,444,000 | - | - |
| Other Gand A | - | - | $42,538,000 | $37,720,000 |
| Impairment Of Capital Assets | - | - | - | $0 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-443,316,000 | $-86,012,000 | $-249,172,000 | $-254,119,000 |
| Total Assets | $792,182,000 | $393,843,000 | $475,198,000 | $295,282,000 |
| Total Non Current Assets | $500,603,000 | $125,537,000 | $101,805,000 | $60,386,000 |
| Other Non Current Assets | $20,874,000 | $27,494,000 | $7,426,000 | $9,718,000 |
| Investmentin Financial Assets | $5,012,000 | $5,482,000 | $7,155,000 | $1,961,000 |
| Goodwill And Other Intangible Assets | $392,294,000 | $7,196,000 | $3,004,000 | $3,581,000 |
| Other Intangible Assets | $324,699,000 | $5,265,000 | $1,073,000 | $1,153,000 |
| Current Assets | $291,579,000 | $268,306,000 | $373,393,000 | $234,896,000 |
| Other Current Assets | $46,553,000 | $31,360,000 | $34,848,000 | $25,477,000 |
| Inventory | $35,313,000 | $27,886,000 | $28,545,000 | $21,772,000 |
| Receivables | $38,367,000 | $11,804,000 | $14,901,000 | $16,801,000 |
| Accounts Receivable | $38,367,000 | $11,804,000 | $14,901,000 | $16,801,000 |
| Allowance For Doubtful Accounts Receivable | $-13,601,000 | $-13,044,000 | $-8,841,000 | $-6,644,000 |
| Gross Accounts Receivable | $51,968,000 | $24,848,000 | $23,742,000 | $23,445,000 |
| Cash Cash Equivalents And Short Term Investments | $171,346,000 | $197,256,000 | $295,099,000 | $170,846,000 |
| Cash And Cash Equivalents | $74,882,000 | $46,339,000 | $238,480,000 | $69,767,000 |
| Restricted Cash | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Cash Financial | - | - | - | - |
| Debt | ||||
| Net Debt | $279,759,000 | - | $30,219,000 | $203,723,000 |
| Total Debt | $367,440,000 | $50,119,000 | $272,624,000 | $278,833,000 |
| Long Term Debt And Capital Lease Obligation | $329,050,000 | $47,696,000 | $252,624,000 | $278,833,000 |
| Long Term Debt | $318,361,000 | $36,051,000 | $248,699,000 | $273,490,000 |
| Current Debt And Capital Lease Obligation | $38,390,000 | $2,423,000 | $20,000,000 | $9,565,000 |
| Current Debt | $36,280,000 | - | $20,000,000 | $9,565,000 |
| Other Current Borrowings | $36,280,000 | - | $20,000,000 | $9,565,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $843,204,000 | $472,659,000 | $721,366,000 | $545,820,000 |
| Total Non Current Liabilities Net Minority Interest | $672,173,000 | $390,822,000 | $617,241,000 | $478,524,000 |
| Other Non Current Liabilities | $303,146,000 | $291,966,000 | $294,767,000 | $161,952,000 |
| Non Current Deferred Liabilities | $39,977,000 | $51,160,000 | $69,794,000 | $37,684,000 |
| Current Liabilities | $171,031,000 | $81,837,000 | $104,125,000 | $67,296,000 |
| Other Current Liabilities | $51,291,000 | $26,700,000 | $28,944,000 | $23,677,000 |
| Current Deferred Liabilities | $15,331,000 | $12,407,000 | $10,508,000 | $3,037,000 |
| Payables And Accrued Expenses | $65,728,000 | $39,503,000 | $44,072,000 | $39,569,000 |
| Interest Payable | $2,152,000 | $303,000 | $2,153,000 | $2,201,000 |
| Payables | $9,034,000 | $6,792,000 | $11,141,000 | $11,052,000 |
| Accounts Payable | $9,034,000 | $6,792,000 | $9,580,000 | $11,052,000 |
| Total Tax Payable | - | $49,000 | $1,561,000 | $0 |
| Income Tax Payable | - | $49,000 | $1,561,000 | $0 |
| Tradeand Other Payables Non Current | - | - | - | $55,000 |
| Equity | ||||
| Common Stock Equity | $-51,022,000 | $-78,816,000 | $-246,168,000 | $-250,538,000 |
| Total Equity Gross Minority Interest | $-51,022,000 | $-78,816,000 | $-246,168,000 | $-250,538,000 |
| Stockholders Equity | $-51,022,000 | $-78,816,000 | $-246,168,000 | $-250,538,000 |
| Gains Losses Not Affecting Retained Earnings | $115,000 | $1,109,000 | $0 | - |
| Other Equity Adjustments | $115,000 | $1,109,000 | - | - |
| Retained Earnings | $-3,195,956,000 | $-3,201,819,000 | $-3,229,407,000 | $-3,217,469,000 |
| Other | ||||
| Ordinary Shares Number | $307,832,587 | $302,959,782 | $270,034,495 | $263,793,305 |
| Share Issued | $307,832,587 | $302,959,782 | $270,034,495 | $263,793,305 |
| Tangible Book Value | $-443,316,000 | $-86,012,000 | $-249,172,000 | $-254,119,000 |
| Invested Capital | $303,619,000 | $-42,765,000 | $22,531,000 | $22,952,000 |
| Working Capital | $120,548,000 | $186,469,000 | $269,268,000 | $167,600,000 |
| Capital Lease Obligations | $12,799,000 | $14,068,000 | $3,925,000 | $5,343,000 |
| Total Capitalization | $267,339,000 | $-42,765,000 | $2,531,000 | $22,952,000 |
| Additional Paid In Capital | $3,141,741,000 | $3,118,865,000 | $2,980,539,000 | $2,964,293,000 |
| Capital Stock | $3,078,000 | $3,029,000 | $2,700,000 | $2,638,000 |
| Common Stock | $3,078,000 | $3,029,000 | $2,700,000 | $2,638,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $39,977,000 | $51,160,000 | $69,794,000 | $37,684,000 |
| Long Term Capital Lease Obligation | $10,689,000 | $11,645,000 | $3,925,000 | $5,343,000 |
| Current Deferred Revenue | $15,331,000 | $12,407,000 | $9,085,000 | $1,733,000 |
| Current Capital Lease Obligation | $2,110,000 | $2,423,000 | - | - |
| Current Provisions | $291,000 | $804,000 | $601,000 | $1,013,000 |
| Current Accrued Expenses | $56,694,000 | $32,711,000 | $32,931,000 | $28,517,000 |
| Investments And Advances | $5,012,000 | $5,482,000 | $7,155,000 | $1,961,000 |
| Available For Sale Securities | $5,012,000 | $5,482,000 | - | - |
| Goodwill | $67,595,000 | $1,931,000 | $1,931,000 | $2,428,000 |
| Net PPE | $82,423,000 | $85,365,000 | $84,220,000 | $45,126,000 |
| Accumulated Depreciation | $-113,913,000 | $-106,676,000 | $-101,536,000 | $-98,560,000 |
| Gross PPE | $196,336,000 | $192,041,000 | $185,756,000 | $143,686,000 |
| Construction In Progress | $6,397,000 | $6,149,000 | $48,997,000 | $16,706,000 |
| Machinery Furniture Equipment | $80,687,000 | $76,815,000 | $72,138,000 | $69,764,000 |
| Buildings And Improvements | $108,377,000 | $108,202,000 | $63,746,000 | $56,341,000 |
| Land And Improvements | $875,000 | $875,000 | $875,000 | $875,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $9,469,000 | $11,041,000 | $8,637,000 | $2,218,000 |
| Work In Process | $11,087,000 | $10,661,000 | $13,646,000 | $13,815,000 |
| Raw Materials | $14,757,000 | $6,184,000 | $6,262,000 | $5,739,000 |
| Other Short Term Investments | $96,464,000 | $150,917,000 | $56,619,000 | $101,079,000 |
| Non Current Accrued Expenses | - | $0 | $56,000 | $55,000 |
| Treasury Shares Number | - | - | $0 | - |
| Held To Maturity Securities | - | - | $7,155,000 | $1,961,000 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $13,689,000 | $32,818,000 | $-8,347,000 | $-88,268,000 |
| Operating Activities | ||||
| Operating Cash Flow | $18,255,000 | $42,511,000 | $34,094,000 | $-80,679,000 |
| Cash Flow From Continuing Operating Activities | $18,255,000 | $42,511,000 | $34,094,000 | $-80,679,000 |
| Operating Gains Losses | $14,158,000 | $18,087,000 | $2,086,000 | $-3,879,000 |
| Investing Activities | ||||
| Capital Expenditure | $-4,566,000 | $-9,693,000 | $-42,441,000 | $-7,589,000 |
| Investing Cash Flow | $-304,803,000 | $-96,649,000 | $-1,988,000 | $4,874,000 |
| Cash Flow From Continuing Investing Activities | $-304,803,000 | $-96,649,000 | $-1,988,000 | $4,874,000 |
| Net Other Investing Changes | $-10,000,000 | $396,000 | $382,000 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $6,887,000 | $19,790,000 |
| Financing Cash Flow | $315,099,000 | $-137,266,000 | $136,607,000 | $21,388,000 |
| Cash Flow From Continuing Financing Activities | $315,099,000 | $-137,266,000 | $136,607,000 | $21,388,000 |
| Net Other Financing Charges | $-11,893,000 | $-7,237,000 | $134,567,000 | $-1,168,000 |
| Net Common Stock Issuance | $0 | $0 | $6,887,000 | $19,790,000 |
| Common Stock Issuance | $0 | $0 | $6,887,000 | $19,790,000 |
| Other | ||||
| Repayment Of Debt | $0 | $-133,168,000 | $-6,667,000 | $0 |
| Issuance Of Debt | $325,000,000 | $0 | $0 | $0 |
| Interest Paid Supplemental Data | $14,716,000 | $17,506,000 | $18,279,000 | $8,852,000 |
| Income Tax Paid Supplemental Data | $1,705,000 | $4,262,000 | $0 | - |
| End Cash Position | $75,627,000 | $47,076,000 | $238,480,000 | $69,767,000 |
| Beginning Cash Position | $47,076,000 | $238,480,000 | $69,767,000 | $124,184,000 |
| Changes In Cash | $28,551,000 | $-191,404,000 | $168,713,000 | $-54,417,000 |
| Proceeds From Stock Option Exercised | $1,992,000 | $3,139,000 | $1,820,000 | $2,766,000 |
| Net Issuance Payments Of Debt | $325,000,000 | $-133,168,000 | $-6,667,000 | $0 |
| Net Long Term Debt Issuance | $325,000,000 | $-133,168,000 | $-6,667,000 | $0 |
| Long Term Debt Payments | $0 | $-133,168,000 | $-6,667,000 | $0 |
| Long Term Debt Issuance | $325,000,000 | $0 | $0 | $0 |
| Net Investment Purchase And Sale | $57,505,000 | $-86,956,000 | $40,453,000 | $27,804,000 |
| Sale Of Investment | $215,308,000 | $193,839,000 | $119,548,000 | $107,340,000 |
| Purchase Of Investment | $-157,803,000 | $-280,795,000 | $-79,095,000 | $-79,536,000 |
| Net Business Purchase And Sale | $-347,742,000 | $0 | $0 | $-15,341,000 |
| Purchase Of Business | $-347,742,000 | $0 | $0 | $-15,341,000 |
| Net PPE Purchase And Sale | $-4,566,000 | $-9,693,000 | $-42,441,000 | $-7,589,000 |
| Purchase Of PPE | $-4,566,000 | $-9,693,000 | $-42,441,000 | $-7,589,000 |
| Change In Working Capital | $-50,883,000 | $-36,473,000 | $16,729,000 | $-24,054,000 |
| Change In Other Working Capital | $-8,259,000 | $-15,312,000 | $39,462,000 | $14,097,000 |
| Change In Other Current Liabilities | $-873,000 | $-4,982,000 | $-11,809,000 | $-9,018,000 |
| Change In Other Current Assets | $-1,909,000 | $-3,570,000 | $263,000 | $523,000 |
| Change In Payables And Accrued Expense | $-18,424,000 | $-5,491,000 | $5,133,000 | $3,373,000 |
| Change In Accrued Expense | $3,256,000 | $-2,703,000 | $6,606,000 | $-723,000 |
| Change In Payable | $-21,680,000 | $-2,788,000 | $-1,473,000 | $4,096,000 |
| Change In Account Payable | $-16,711,000 | $-2,788,000 | $-1,473,000 | $4,096,000 |
| Change In Tax Payable | $-4,969,000 | $0 | $0 | - |
| Change In Income Tax Payable | $-4,969,000 | $0 | $0 | - |
| Change In Prepaid Assets | $-10,032,000 | $-6,574,000 | $-7,318,000 | $-15,552,000 |
| Change In Inventory | $-6,624,000 | $-3,196,000 | $-11,347,000 | $-5,670,000 |
| Change In Receivables | $-4,762,000 | $2,652,000 | $2,345,000 | $-11,807,000 |
| Changes In Account Receivables | $-4,762,000 | $2,652,000 | $2,345,000 | $-11,807,000 |
| Other Non Cash Items | $4,888,000 | $5,817,000 | $1,384,000 | $11,986,000 |
| Stock Based Compensation | $24,195,000 | $21,358,000 | $17,649,000 | $13,447,000 |
| Asset Impairment Charge | $10,397,000 | $3,855,000 | $4,574,000 | $2,202,000 |
| Amortization Of Securities | $-2,647,000 | $-5,092,000 | $-925,000 | $707,000 |
| Depreciation Amortization Depletion | $12,284,000 | $7,371,000 | $4,535,000 | $6,312,000 |
| Depreciation And Amortization | $12,284,000 | $7,371,000 | $4,535,000 | $6,312,000 |
| Depreciation | $12,284,000 | $7,371,000 | $4,535,000 | $6,312,000 |
| Gain Loss On Investment Securities | $6,409,000 | $1,550,000 | $170,000 | $932,000 |
| Net Foreign Currency Exchange Gain Loss | $7,749,000 | $-3,907,000 | $1,916,000 | $-4,811,000 |
| Net Income From Continuing Operations | $5,863,000 | $27,588,000 | $-11,938,000 | $-87,400,000 |
| Gain Loss On Sale Of PPE | - | $565,000 | $0 | $0 |
| Change In Interest Payable | - | - | $0 | $0 |
| Net Intangibles Purchase And Sale | - | - | - | $0 |
| Purchase Of Intangibles | - | - | - | $0 |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Payments | - | - | - | - |
Fetched: 2026-06-20